Taxanes Synergize with the Bispecific Antibody MDXH447 to Enhance Antibody-Dependent Cell-Mediated Cytotoxicity

Journal of Chemotherapy

Volumn 15, Issue 5, 2003, Pages 472-479

  Tretter, C P G ^a,b   Lewis, L D ^a,b   Fisher, J ^a,b   Waugh, M G ^a,b   Ernstoff, M S ^a,b  

^a NORRIS COTTON CANCER CENTER   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Antibody; Bispecific; Cytotoxicity; Synergy; Taxane

Indexed keywords

BISPECIFIC ANTIBODY; DOCETAXEL; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MDXH447; PACLITAXEL; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; SQUAMOUS CELL CARCINOMA;

EID: 0142248186     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2003.15.5.472     Document Type: Article

References (22)

1. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L et al. Multinational study of the efficacy and safety of humanized anti-HER-2 monoclonal antibody in women who have HER-2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639.
2. Manthey CL, Perera PY, Salkowski CA, Vogel NS. Taxol prvides a second signal for murine macrophage tumoricidal activity. J Immunol 1994; 152: 825.
3. McLaughlin P, Grillo-Lopez AJ, Link BD et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825.
4. Kalechman Y, Longo DL, Catane R, Shani A, Albeck M, Sredni B. Synergistic anti-tumoral effect of paclitaxel (Taxol)+AS101 in a murine model of B16 melanoma: association with ras-dependent signal-transduction pathways. International Journal of Cancer 2000; 86: 281.
5. Mehta S, Blackinton D, Manfredi M, Rajaratnam D, Kouttab N, Wanebo H. Taxol pretreatment of tumor targets amplifies natural killer cell-mediated lysis. Leuk & Lymph 1997; 26: 67.
6. Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268.
7. Deo YM, Graziano RF, Repp R, van de Winkel JGJ. Clinical significance of IgG Fc receptors and Fcg R-directed immunotherapies. Immunol Today 1997; 18: 127.
8. Goldstein J, Graziano RF, Sundarapandiyan K, Somasundaram C, Deo YM. Cytolytic and cytostatic prperties of an anti-human Fcg RI (CD64) x epidermal growth factor bispecific fusion protein. J Immunol 1997; 158: 872.
9. Stockmeyer B, Valerius T, Repp R et al. Preclinical studies with FcgR bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer. Cancer Res 1997; 57: 696.
10. Mentzer SJ, Guyre PM, Burakoff SJ, Faller DV. Spontaneous aggregation as a mechanism for human monocyte purification. Cellular Immunology 1986; 101: 312.
11. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27.
12. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994; 86: 1517.
13. Barrett JM, Kruczynski A, Etievant C, Hill BT. Synergistic effects of F 11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents. Cancer Chemother Pharmacol 2002; 49: 479.
14. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharm Rev 1995; 47: 331.
15. Pegram M, Hsu S, Lewis G et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999; 18: 2241.
16. Chan OTM, Yang LX. The immunological effects of taxanes Can Immunol Immunother 2000; 49: 181-185.
17. Kroesen BJ, Wellenberg GJ, Bakker A, Helfrich W, The TH, de Leij L. The role of apoptosis in bispecific antibody-mediated T-cell cytotoxicity. Br J Cancer 1996; 73: 721.
18. Peng D, Fan Z, Lu Y, DeBlasio T, Scher H, Mendelsohn J. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res 1996; 56: 3666.
19. Renner C, Held G, Ohnesorge S et al. Role of perforin, granzymes and the proliferative state of the target cells in apoptosis and necrosis mediated by bispecific-antibody-activated cytotoxic T cells. Can Immunol Immunother 1997; 44: 70.
20. Takamuku K, Baba K, Arinaga S, Li J, Mori M, Akiyoshi T. Apoptosis in antibody-dependent monocyte-mediated cytotoxicity with monoclonal antibody-dependent monocyte-mediated cytotoxicity with monoclonal antibody 17-1A against human colorectal carcinoma cells: enhancement with interferon gamma. Can Immunol Immunother 1996; 43: 220.
21. Mabuchi S, Ohmichi M, Kimura A et al. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem 2002; 277(36): 33490-500.
22. Calabrese EJ, Baldwin LA. Defining hormesis. Human Exp Toxicol 2002; 21: 91.